Conditions: Diffuse Large B-Cell Lymphoma
Keywords: lymphoma DLBCL fostamatinib Diffuse Large B-Cell Lymphoma (DLBCL)
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 101
Healthy volunteers: no

Brief summary:
This study will evaluate the effectiveness of fostamatinib (200 mg twice a day) in patients with worsening or unmanageable lymphoma with a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (abbreviated as DLBCL)

Detailed description:
Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Arms:
arm 1: 200mg fostamatinib bid n=60

Interventions: intervention 1: Fostamatinib
Intervention descriptions: intervention 1: Phase II Trial to evaluate the efficacy of 200mg fostamatinib

Protocol document: